In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y ... in August after the FDA removed semaglutide from ...